I’m embarrassing myself lol your 10 paragraph type up was the...

I’m embarrassing myself lol your 10 paragraph type up was the most generic post which can be posted on any biotech on the ASX. Post up research associated with NYR rather than posting up a generic message.

1. Firstly you don’t even know the science behind NYR and AGN. They both work by inhibiting calcium influx into neurons one does it via Glutamate inhibition and NYR does it via the actual TRPC channels. That is why NYR can be used not only to protect the brain from secondary brain injury because it can be dosed over multiple days compared to AGN but protect heart muscle from death and for reducing arrhythmias leading to sudden cardiac arrest. NYR is a complete prevention for stroke and heart attacks, AGN only deals with primary brain injury
2. Secondly the stock is moving because they are about one month from clearing safety in humans after clearing 75 percent of their safety study in humans in a 60 billion dollar unmet space
3. Thirdly the CEO in today’s interview stated clearly they are now developing plans for phase 2 this year.

Every director, board member and major shareholder has increased their holdings. NA-1 has already proved up reducing calcium influx, reduces brain injury, AGN is about to release their results and will show the same because all have the same mechanism of reducing brain injury. It’s a given what’s coming and yes NYR at current 25 million dollar valuation is hugely undervalued compared to its peers which NYR has a Swisse Army drug compared to the others